Peps
What is Survodutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Biological role or research focus
Obesity research.
The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Role reference: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Names you may encounter
BI 456906
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Dual GLP-1 / glucagon receptor agonist
- Research focus
- Obesity research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Molecular structure
How Survodutide works
It engages GLP-1 and glucagon receptor pathways. The relevant evidence is the balance of measured weight outcomes and harms, rather than a presumed benefit from engaging two receptors.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Clinical context & research status
The selected publication describes investigational treatment in obesity research. It does not establish the identity, effectiveness, or safety of a seller’s research vial.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2026
SYNCHRONIZE-1
How did weight change over 76 weeks?
- Population / model
- 725 adults without diabetes who had obesity, or overweight with an associated condition.
- Study design
- Double-blind randomized phase 3 trial, two survodutide groups versus placebo, with lifestyle counseling over 76 weeks.
- Main finding
- Mean weight changes in the treatment-regimen analysis were −12.2% and −13.0% versus −5.4% with placebo. Gastrointestinal adverse events occurred in 80.9%, 89.7%, and 47.9%, respectively.
- Limits & context
- The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. ↗
Diabetes care · 2024 Nov 1 · Journal Article, Review, Research Support, Non-U.S. Gov't
Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. ↗
Hepatology (Baltimore, Md.) · 2025 Dec 1 · Journal Article, Systematic Review, Comparative Study, Network Meta-Analysis, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Read available full text ↗
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. ↗
Alimentary pharmacology & therapeutics · 2025 Jun · Journal Article, Review
Read available full text ↗
Weight management treatment in obesity. ↗
Medicina clinica · 2025 Nov · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Gastrointestinal events were substantially more frequent in the active-treatment groups. The absence of reported deaths in this trial cannot establish absence of rare serious harms.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Identity, route, and evidence limits
The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
3 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Hem Zayıflatıyor Hem Karaciğeri Koruyor: Survodutide Nedir? ↗
Title match · Captions not indexed
Biohackingturkey
Survodutide: Obezite ve Diyabete Karşı Çift Etkili Yeni Silah! ↗
Title match · Captions not indexed
Dr. Jones, DC
New weight loss medication Survodutide in phase 3 clinical trials! (Full vid on TikTok) #shorts ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Why does the analysis method matter?
- What population, comparator, and route were actually studied?
- The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Why does the analysis method matter?
An analysis that includes discontinuation answers a different question from one estimating outcomes if everyone remained on treatment. Read the population and estimand before comparing percentages.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Survodutide Once Weekly for the Treatment of Adults with Obesity. · 2026 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.